Researchers Identify New Mechanism of Taxane Resistance

Share this content:

(ChemotherapyAdvisor) – Researchers at the University of Alberta, Edmonton, Alberta, Canada, have published a study that identifies a new mechanism of resistance for the commonly used chemotherapeutic agent paclitaxel.

The study, entitled “The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis”, was published in the March 19 issue of Oncogene. Although the anti-mitotic taxanes paclitaxel and docetaxel are widely used for the treatment of breast, ovarian, and lung cancers, their mechanism of resistance is not completely understood. It is known that paclitaxel induces apoptosis and also modulates autophagy, but the mechanism by which autophagy affects paclitaxel activity is unclear.  

“We discovered that paclitaxel inhibited autophagy through two distinct mechanisms dependent on cell cycle stage,” the authors wrote. “In mitotic cells, paclitaxel blocked activation of the class 3 phosphatidyl inositol 3 kinase, Vps34, a critical initiator of autophagosome formation. In non-mitotic paclitaxel-treated cells, autophagosomes were generated but their movement and maturation was inhibited.”

When the researchers inhibited autophagosome formation either chemically or genetically, they diminished paclitaxel-induced cell death, leading the researchers to suggest that autophagosome accumulation sensitized cancer cells to paclitaxel toxicity. It was further observed that when primary breast tumors expressed diminished levels of autophagy-initiating genes, they were resistant to taxane therapy.

The researchers concluded that the chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis, suggesting possible mechanisms and prognostic markers of clinical taxane resistance.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs